Sandra R. Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra R. Wilson has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jun Ma
Palo Alto Medical Foundation Research Institute, Palo Alto, California
4 shared publications - Lan Xiao
Department of Health Services Research Palo Alto Medical Foundation Research Institute California USA
4 shared publications Sarah B. Knowles
Palo Alto Medical Foundation Research Institute, Palo Alto, Calif
4 shared publicationsPhilip W. Lavori
Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA
3 shared publications- Randall Scott Stafford
Affiliation Stanford University School of Medicine, Stanford Prevention Research Center, Stanford, California, United States of America
3 shared publications Arlene Fink
University of California at Los Angeles
2 shared publications
Latest Publications
- 1 March 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (3) , 1085-1095
A new measure to assess asthma's effect on quality of life from the patient's perspective
- 1 March 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (3) , 1085-1095
A new measure to assess asthma's effect on quality of life from the patient's perspective
- 1 January 2016
- Published by Springer Nature
- p. 105-133
Health Disparities as They Relate to Medication Adherence
- 1 January 2016
- Published by Springer Nature
- p. 105-133
Health Disparities as They Relate to Medication Adherence
- 8 October 2013
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 29 (2) , 312-319
The Prevalence of Harmful and Hazardous Alcohol Consumption in Older U.S. Adults: Data from the 2005–2008 National Health and Nutrition Examination Survey (NHANES)
Alcohol consumption and its interaction with disease, medication use, and functional status may result in serious health problems, but little information exists about the national prevalence of alcohol-related health risk in older adults. To estimate the prevalence of harmful and hazardous alcohol use and the prevalence of consumption in excess of National Institute of Alcohol Abuse and Alcoholism (NIAAA) recommendations, in people aged 65 and older, and by sex and race/ethnicity sub-group. Cross-sectional, using data from the 2005–2008 National Health and Nutrition Examination Survey of the non-institutionalized U.S. population. One thousand and eighty-three respondents aged 65 and older who consume alcohol. Participants’ alcohol consumption was classified as Harmful, Hazardous, or Healthwise, in the context of their specific health status, using the Alcohol-Related Problems Survey classification algorithm. Overall, 14.5 % of older drinkers (95 % CI: 12.1 %, 16.8 %) consumed alcohol above the NIAAA’s recommended limits. However, when health status was taken into account, 37.4 % of older drinkers (95 % CI: 34.9 %, 40.0 %) had Harmful consumption and 53.3 % (95 % CI: 50.1 %, 56.6 %) had either Hazardous or Harmful consumption. Among light/moderate drinkers, the proportions were 17.7 % (95 % CI: 14.7 %, 20.7 %) and 28.0 % (95 % CI: 24.8 %, 31.1 %), respectively. Male drinkers had significantly greater odds of Hazardous/Harmful consumption than female drinkers (OR = 2.14 [95 % CI: 1.77, 2.6]). Black drinkers had worse health status and significantly greater odds of Hazardous/Harmful consumption than white drinkers (OR = 1.49; 95 % CI: 1.02, 2.17), despite having no greater prevalence of drinking in excess of NIAAA-recommended limits. Most older Americans who drink are light/moderate drinkers, yet substantial proportions of such drinkers drink in a manner that is either harmful or hazardous to their health. Older adults with risky alcohol consumption are unlikely to be identified by health care providers if clinicians rely solely on whether patient consumption exceeds the NIAAA-recommended limits.
- 8 October 2013
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 29 (2) , 312-319
The Prevalence of Harmful and Hazardous Alcohol Consumption in Older U.S. Adults: Data from the 2005–2008 National Health and Nutrition Examination Survey (NHANES)
Alcohol consumption and its interaction with disease, medication use, and functional status may result in serious health problems, but little information exists about the national prevalence of alcohol-related health risk in older adults. To estimate the prevalence of harmful and hazardous alcohol use and the prevalence of consumption in excess of National Institute of Alcohol Abuse and Alcoholism (NIAAA) recommendations, in people aged 65 and older, and by sex and race/ethnicity sub-group. Cross-sectional, using data from the 2005–2008 National Health and Nutrition Examination Survey of the non-institutionalized U.S. population. One thousand and eighty-three respondents aged 65 and older who consume alcohol. Participants’ alcohol consumption was classified as Harmful, Hazardous, or Healthwise, in the context of their specific health status, using the Alcohol-Related Problems Survey classification algorithm. Overall, 14.5 % of older drinkers (95 % CI: 12.1 %, 16.8 %) consumed alcohol above the NIAAA’s recommended limits. However, when health status was taken into account, 37.4 % of older drinkers (95 % CI: 34.9 %, 40.0 %) had Harmful consumption and 53.3 % (95 % CI: 50.1 %, 56.6 %) had either Hazardous or Harmful consumption. Among light/moderate drinkers, the proportions were 17.7 % (95 % CI: 14.7 %, 20.7 %) and 28.0 % (95 % CI: 24.8 %, 31.1 %), respectively. Male drinkers had significantly greater odds of Hazardous/Harmful consumption than female drinkers (OR = 2.14 [95 % CI: 1.77, 2.6]). Black drinkers had worse health status and significantly greater odds of Hazardous/Harmful consumption than white drinkers (OR = 1.49; 95 % CI: 1.02, 2.17), despite having no greater prevalence of drinking in excess of NIAAA-recommended limits. Most older Americans who drink are light/moderate drinkers, yet substantial proportions of such drinkers drink in a manner that is either harmful or hazardous to their health. Older adults with risky alcohol consumption are unlikely to be identified by health care providers if clinicians rely solely on whether patient consumption exceeds the NIAAA-recommended limits.
- Open Access
Short‐term weight loss patterns, baseline predictors, and longer‐term follow‐up within a randomized controlled trial
Objective To examine weight loss patterns and predictors among participants in a primary care‐based translation study of the Diabetes Prevention Program lifestyle intervention. Design and Methods Cluster analysis identified short‐term (12‐week) weight loss patterns among 72 intervention participants. Analysis of variance assessed cluster differences in weight loss maintenance at 15‐month follow‐up. Discriminant analysis identified baseline characteristics that best differentiated between clusters. Results Participants had baseline mean (SD) age of 55.0 (10.8) years and BMI of 31.9 (5.2) kg/m2. Cluster analysis identified three short‐term weight loss patterns: modest (n = 15; 21%), moderate‐and‐steady (n = 43; 60%), and substantial‐and‐early (n = 14; 19%). Only participants with the latter two patterns achieved clinically significant (≥5%) short‐term weight loss and maintained it at 15 months. On discriminant analysis, the modest cluster was most differentiated from other clusters by high friend encouragement for dietary change, high obesity‐related problems, and low physical well‐being. The moderate‐and‐steady cluster was differentiated by lower physical activity, family encouragement, and depression symptoms. Conclusion Results provided insight into the heterogeneity of response to an effective lifestyle intervention by identifying short‐term weight loss patterns and their baseline predictors and relationship to 15‐month success. If replicated, results may help tailor strategies for participant subgroups in weight loss programs.
Open AccessShort‐term weight loss patterns, baseline predictors, and longer‐term follow‐up within a randomized controlled trial
Objective To examine weight loss patterns and predictors among participants in a primary care‐based translation study of the Diabetes Prevention Program lifestyle intervention. Design and Methods Cluster analysis identified short‐term (12‐week) weight loss patterns among 72 intervention participants. Analysis of variance assessed cluster differences in weight loss maintenance at 15‐month follow‐up. Discriminant analysis identified baseline characteristics that best differentiated between clusters. Results Participants had baseline mean (SD) age of 55.0 (10.8) years and BMI of 31.9 (5.2) kg/m2. Cluster analysis identified three short‐term weight loss patterns: modest (n = 15; 21%), moderate‐and‐steady (n = 43; 60%), and substantial‐and‐early (n = 14; 19%). Only participants with the latter two patterns achieved clinically significant (≥5%) short‐term weight loss and maintained it at 15 months. On discriminant analysis, the modest cluster was most differentiated from other clusters by high friend encouragement for dietary change, high obesity‐related problems, and low physical well‐being. The moderate‐and‐steady cluster was differentiated by lower physical activity, family encouragement, and depression symptoms. Conclusion Results provided insight into the heterogeneity of response to an effective lifestyle intervention by identifying short‐term weight loss patterns and their baseline predictors and relationship to 15‐month success. If replicated, results may help tailor strategies for participant subgroups in weight loss programs.
- Open Access
- 28 January 2013
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 173 (2) , 113-121
Translating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss Into Primary Care
An estimated 69% of US adults are overweight or obese,1 and those with modifiable cardiometabolic risk factors are a critical target group for intervention.2,3 Lifestyle modification focused on modest (5%-10%) weight loss and moderate-intensity physical activity can significantly reduce the incidence of type 2 diabetes mellitus (DM) (as much as 58% as shown in the Diabetes Prevention Program [DPP]) and cardiometabolic risk factors in high-risk individuals,4-6 with benefits sustained for at least 10 years.7 Evidence-based guidelines therefore recommend effective lifestyle intervention for weight management and disease prevention.8,9
- 28 January 2013
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 173 (2) , 113-121
Open AccessTranslating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss Into Primary Care
An estimated 69% of US adults are overweight or obese,1 and those with modifiable cardiometabolic risk factors are a critical target group for intervention.2,3 Lifestyle modification focused on modest (5%-10%) weight loss and moderate-intensity physical activity can significantly reduce the incidence of type 2 diabetes mellitus (DM) (as much as 58% as shown in the Diabetes Prevention Program [DPP]) and cardiometabolic risk factors in high-risk individuals,4-6 with benefits sustained for at least 10 years.7 Evidence-based guidelines therefore recommend effective lifestyle intervention for weight management and disease prevention.8,9
- 1 November 2012
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 130 (5) , 1085-1086
Adding measures to the asthma outcome measurement toolbox: New findings, new issues
- 1 November 2012
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 130 (5) , 1085-1086
Adding measures to the asthma outcome measurement toolbox: New findings, new issues
- Open Access
- 24 March 2010
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 10 (1) , 16
The Breathe Easier through Weight Loss Lifestyle (BE WELL) Intervention: A randomized controlled trial
Obesity and asthma have reached epidemic proportions in the US. Their concurrent rise over the last 30 years suggests that they may be connected. Numerous observational studies support a temporally-correct, dose-response relationship between body mass index (BMI) and incident asthma. Weight loss, either induced by surgery or caloric restriction, has been reported to improve asthma symptoms and lung function. Due to methodological shortcomings of previous studies, however, well-controlled trials are needed to investigate the efficacy of weight loss strategies to improve asthma control in obese individuals. BE WELL is a 2-arm parallel randomized clinical trial (RCT) of the efficacy of an evidence-based, comprehensive, behavioral weight loss intervention, focusing on diet, physical activity, and behavioral therapy, as adjunct therapy to usual care in the management of asthma in obese adults. Trial participants (n = 324) are patients aged 18 to 70 years who have suboptimally controlled, persistent asthma, BMI between 30.0 and 44.9 kg/m2, and who do not have serious comorbidities (e.g., diabetes, heart disease, stroke). The 12-month weight loss intervention to be studied is based on the principles of the highly successful Diabetes Prevention Program lifestyle intervention. Intervention participants will attend 13 weekly group sessions over a four-month period, followed by two monthly individual sessions, and will then receive individualized counseling primarily by phone, at least bi-monthly, for the remainder of the intervention. Follow-up assessment will occur at six and 12 months. The primary outcome variable is the overall score on the Juniper Asthma Control Questionnaire measured at 12 months. Secondary outcomes include lung function, asthma-specific and general quality of life, asthma medication use, asthma-related and total health care utilization. Potential mediators (e.g., weight loss and change in physical activity level and nutrient intake) and moderators (e.g., socio-demographic characteristics and comorbidities) of the intervention effects also will be examined. This RCT holds considerable potential for illuminating the nature of the obesity-asthma relationship and advancing current guidelines for treating obese adults with asthma, which may lead to reduced morbidity and mortality related to the comorbidity of the two disorders. NCT00901095
- 24 March 2010
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 10 (1) , 16
Open AccessThe Breathe Easier through Weight Loss Lifestyle (BE WELL) Intervention: A randomized controlled trial
Obesity and asthma have reached epidemic proportions in the US. Their concurrent rise over the last 30 years suggests that they may be connected. Numerous observational studies support a temporally-correct, dose-response relationship between body mass index (BMI) and incident asthma. Weight loss, either induced by surgery or caloric restriction, has been reported to improve asthma symptoms and lung function. Due to methodological shortcomings of previous studies, however, well-controlled trials are needed to investigate the efficacy of weight loss strategies to improve asthma control in obese individuals. BE WELL is a 2-arm parallel randomized clinical trial (RCT) of the efficacy of an evidence-based, comprehensive, behavioral weight loss intervention, focusing on diet, physical activity, and behavioral therapy, as adjunct therapy to usual care in the management of asthma in obese adults. Trial participants (n = 324) are patients aged 18 to 70 years who have suboptimally controlled, persistent asthma, BMI between 30.0 and 44.9 kg/m2, and who do not have serious comorbidities (e.g., diabetes, heart disease, stroke). The 12-month weight loss intervention to be studied is based on the principles of the highly successful Diabetes Prevention Program lifestyle intervention. Intervention participants will attend 13 weekly group sessions over a four-month period, followed by two monthly individual sessions, and will then receive individualized counseling primarily by phone, at least bi-monthly, for the remainder of the intervention. Follow-up assessment will occur at six and 12 months. The primary outcome variable is the overall score on the Juniper Asthma Control Questionnaire measured at 12 months. Secondary outcomes include lung function, asthma-specific and general quality of life, asthma medication use, asthma-related and total health care utilization. Potential mediators (e.g., weight loss and change in physical activity level and nutrient intake) and moderators (e.g., socio-demographic characteristics and comorbidities) of the intervention effects also will be examined. This RCT holds considerable potential for illuminating the nature of the obesity-asthma relationship and advancing current guidelines for treating obese adults with asthma, which may lead to reduced morbidity and mortality related to the comorbidity of the two disorders. NCT00901095
- Top Cited Papers
- 15 March 2010
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 181 (6) , 566-577
Shared Treatment Decision Making Improves Adherence and Outcomes in Poorly Controlled Asthma
Rationale: Poor adherence to asthma controller medications results in poor treatment outcomes. Objectives: To compare controller medication adherence and clinical outcomes in 612 adults with poorly controlled asthma randomized to one of two different treatment decision-making models or to usual care. Methods: In shared decision making (SDM), nonphysician clinicians and patients negotiated a treatment regimen that accommodated patient goals and preferences. In clinician decision making, treatment was prescribed without specifically eliciting patient goals/preferences. The otherwise identical intervention protocols both provided asthma education and involved two in-person and three brief phone encounters. Measurements and Main Results: Refill adherence was measured using continuous medication acquisition (CMA) indices—the total days' supply acquired per year divided by 365 days. Cumulative controller medication dose was measured in beclomethasone canister equivalents. In follow-up Year 1, compared with usual care, SDM resulted in: significantly better controller adherence (CMA, 0.67 vs. 0.46; P < 0.0001) and long-acting β-agonist adherence (CMA, 0.51 vs. 0.40; P = 0.0225); higher cumulative controller medication dose (canister equivalent, 10.9 vs. 5.2; P < 0.0001); significantly better clinical outcomes (asthma-related quality of life, health care use, rescue medication use, asthma control, and lung function). In Year 2, compared with usual care, SDM resulted in significantly lower rescue medication use, the sole clinical outcome available for that year. Compared with clinician decision making, SDM resulted in: significantly better controller adherence (CMA, 0.67 vs. 0.59; P = 0.03) and long-acting β-agonist adherence (CMA, 0.51 vs. 0.41; P = 0.0143); higher cumulative controller dose (CMA, 10.9 vs. 9.1; P = 0.005); and quantitatively, but not significantly, better outcomes on all clinical measures. Conclusions: Negotiating patients' treatment decisions significantly improves adherence to asthma pharmacotherapy and clinical outcomes. Clinical trials registered with www.clinicaltrials.gov (NCT00217945 and NCT00149526).
- 15 March 2010
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 181 (6) , 566-577
Top Cited PapersShared Treatment Decision Making Improves Adherence and Outcomes in Poorly Controlled Asthma
Rationale: Poor adherence to asthma controller medications results in poor treatment outcomes. Objectives: To compare controller medication adherence and clinical outcomes in 612 adults with poorly controlled asthma randomized to one of two different treatment decision-making models or to usual care. Methods: In shared decision making (SDM), nonphysician clinicians and patients negotiated a treatment regimen that accommodated patient goals and preferences. In clinician decision making, treatment was prescribed without specifically eliciting patient goals/preferences. The otherwise identical intervention protocols both provided asthma education and involved two in-person and three brief phone encounters. Measurements and Main Results: Refill adherence was measured using continuous medication acquisition (CMA) indices—the total days' supply acquired per year divided by 365 days. Cumulative controller medication dose was measured in beclomethasone canister equivalents. In follow-up Year 1, compared with usual care, SDM resulted in: significantly better controller adherence (CMA, 0.67 vs. 0.46; P < 0.0001) and long-acting β-agonist adherence (CMA, 0.51 vs. 0.40; P = 0.0225); higher cumulative controller medication dose (canister equivalent, 10.9 vs. 5.2; P < 0.0001); significantly better clinical outcomes (asthma-related quality of life, health care use, rescue medication use, asthma control, and lung function). In Year 2, compared with usual care, SDM resulted in significantly lower rescue medication use, the sole clinical outcome available for that year. Compared with clinician decision making, SDM resulted in: significantly better controller adherence (CMA, 0.67 vs. 0.59; P = 0.03) and long-acting β-agonist adherence (CMA, 0.51 vs. 0.41; P = 0.0143); higher cumulative controller dose (CMA, 10.9 vs. 9.1; P = 0.005); and quantitatively, but not significantly, better outcomes on all clinical measures. Conclusions: Negotiating patients' treatment decisions significantly improves adherence to asthma pharmacotherapy and clinical outcomes. Clinical trials registered with www.clinicaltrials.gov (NCT00217945 and NCT00149526).
- Open Access
- 1 January 2010
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 8 (1) , 77
Development of the ATAQ-IPF: a tool to assess quality of life in IPF
There is no disease-specific instrument to assess health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF).
- 1 January 2010
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 8 (1) , 77
Open AccessDevelopment of the ATAQ-IPF: a tool to assess quality of life in IPF
There is no disease-specific instrument to assess health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF).